Abstract: The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.

Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.

Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.

Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.

Abstract: This invention relates to novel compounds having the formula (I); and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Abstract: The invention relates to a clamping device for removably mounting a tool (3) or a tool fixture in a receiving part (1). Said clamping device comprises several pincers elements (33) which are concentrically arranged around a central axis (32) within the receiving part (1) and are impinged upon by a tension spring (39) so as to be moved into a clamping position in order to brace the tool (3) or the tool fixture. In order to be able to automatically replace a tool without using much force and energy, an axially movable closing element (17) is assigned to the pincers elements (33). Said closing element (17) impinges the pincers elements (33) in a forward position that is advanced in the direction of the pincers elements (33) for mounting purposes in the clamping position thereof, which is swiveled inward by means of the tension spring (39), while being movable into a retracted position with the aid of a detaching device (12, 16, 45, 46, 47) in order to release the pincers elements (3).

Abstract: The invention relates to compounds of the formula I: wherein one of R5, R6 and R7 is and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR ? and/or PPAR? agonists.

Abstract: A fluidized bed is described and which includes a multiplicity of fluidizing manifolds positioned in spaced relation one relative to the others; an enclosure positioned in gravity receiving relation relative to the multiplicity of fluidizing manifolds and which has an intake and a discharge end, and wherein particulate matter received in the fluidized bed moves under the influence of gravity from the intake end to the discharge end, and a moveable gate is mounted on the second discharge end of the enclosure and which is operable to selectively occlude a discharge aperture and which further facilitates the selective removal of particulate matter and waste material entrained with same, and which moves under the influence of gravity to the discharge end thereof.

Abstract: This invention relates to 4,4-disubstituted piperidine derivatives of the formula wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.

Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.

Abstract: This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: A multi-chamber heat accumulator for storing heat energy as well as for generating electrical energy comprises a pit structure having a bottom, a sidewall, and a cover. The pit structure comprises at least one inner zone with a first solid matter pit filling and at least one outer zone with a second solid matter pit filling. The outer zone at least partially surrounds the inner zone, the pit filling of the inner zone being separated at least in parts from the pit filling of the outer zone by at least one partition wall. The inner zone comprises at least one first pipeline system with at least one inlet to the inner zone and at least one outlet from the inner zone for passing fluids through, which is present at least in parts in the first pit filling material of the inner zone. A method for generating electrical energy is also disclosed.

Abstract: The invention pertains to a rotary feed-through for supplying a fluid to a rotating machine part with a hollow shaft (3) that is rotatably supported in a housing (1, 2) and has a first sliding surface (29), with a sealing bushing (31) that is arranged in a rotationally fixed fashion within the housing (1, 2) coaxial to the shaft (3) and has a second sliding surface (30) for contacting the first sliding surface (29), and with a collecting chamber (27) that is arranged within the housing (1, 2) and serves for collecting the leakage fluid escaping between the two sliding surfaces (29, 30). The leakage fluid collected within the rotary feed-through can be monitored with the aid of a detection channel (26, 33, 34, 37, 39, 47) in the housing (1, 2) that is connected to the collecting chamber (27) and contains a leakage sensor (41).

Abstract: This invention relates to compounds of the formula wherein A, R1 to R3 are as defined in the claims and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridinone and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5 such as diabetes mellitus.

Abstract: This invention is concerned with compounds of the formula wherein R1 to R5, R5? and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: The invention relates to compounds of the formula I: wherein one of R5, R6 and R7 is and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR ? and/or PPAR? agonists.

Abstract: This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.